BD a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe.
Biohaven Ltd. a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, highlighted its broad portfolio progress.
AptarGroup, Inc. a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, shared an overview of its growing portfolio of eye care solutions including its new technology, Beat the Blink™, a delivery system designed to improve dosing precision and enhance patient experience by “beating the blink” reflex, currently part of an exclusive partnership with Bausch and Lomb.
Virax Biolabs Group Limited an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones, achievements and clinical progress while outlining its strategic priorities for 2026 in a letter to shareholders and investors.
AstraZeneca’s IMFINZI® in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
For the millions of people worldwide living with severe forms of epilepsy, some do not respond to medication and it can be difficult to find lasting relief. Patients with a severe epileptic condition called focal treatment-resistant epilepsy (FTRE) could experience seizures that start in a specific part of their brain and continue to occur despite significant and appropriate efforts to control them with medication.
Attendees at this year's American Orthopedic Foot and Ankle Society's Annual Meeting in Savannah, Ga., will be the first to see Medline UNITE Foot & Ankle's new FORCECORD™ Midsubstance Achilles Repair System and DEXLOCK® Knotless Double Row Achilles Repair System.
In a category long dominated by legacy brands and artificial additives, a new national survey reveals a powerful shift: U.S. pediatricians overwhelmingly prefer the ingredient profiles in Genexa’s pediatric pain and fever liquid medicines over those in Children’s Tylenol® top-selling comparable products. Genexa is the first clean medicine company, revolutionizing the over-the-counter (OTC) medicine aisle by making medicine with the same effective active ingredients as the leading brands, but without any artificial additives.
Regeneron Pharmaceuticals, Inc. and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the trial, Dupixent® (dupilumab) outperformed Xolair® (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints.
UroGen engages in the development and commercialization of solutions for specialty cancers. The Company’s lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer.